A 2018 study suggests that half the dosage of breast cancer drug Herceptin is just as effective as the one-year dose and carries fewer side effects for those with HER-2 positive breast cancer. But Thomas Froehlich, M.D., says it’s too soon to change treatment recommendations. Learn more.
August 1, 2018